The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease ; volume:9 ; number:1 ; day:26 ; month:10 ; year:2017 ; pages:1-7 ; date:12.2017
Alzheimer's research & therapy ; 9, Heft 1 (26.10.2017), 1-7, 12.2017
- Schlagwort
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Urheber
-
Ritchie, Craig W.
- Beteiligte Personen und Organisationen
-
Russ, Tom C.
Banerjee, Sube
Barber, Bob
Boaden, Andrew
Fox, Nick C.
Holmes, Clive
Isaacs, Jeremy D.
Leroi, Ira
Lovestone, Simon
Norton, Matt
O’Brien, John
Pearson, Jim
Perry, Richard
Pickett, James
Waldman, Adam D.
Wong, Wai Lup
Rossor, Martin N.
Burns, Alistair
SpringerLink (Online service)
- DOI
-
10.1186/s13195-017-0312-4
- URN
-
urn:nbn:de:1111-2017111513357
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ritchie, Craig W.
- Russ, Tom C.
- Banerjee, Sube
- Barber, Bob
- Boaden, Andrew
- Fox, Nick C.
- Holmes, Clive
- Isaacs, Jeremy D.
- Leroi, Ira
- Lovestone, Simon
- Norton, Matt
- O’Brien, John
- Pearson, Jim
- Perry, Richard
- Pickett, James
- Waldman, Adam D.
- Wong, Wai Lup
- Rossor, Martin N.
- Burns, Alistair
- SpringerLink (Online service)
Ähnliche Objekte (12)
Disease-modifying treatments in Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment
Disease-modifying treatments in Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment
Disease-modifying treatments in Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease